Table 1. RGD-A-TNF Dose Escalation Study: Patient Population and RGD-A-TNF Trafficking Data.
| Dose (TU) | Cohort | *Patient I.D. | Post tx. biopsy | Tumor histology | Tumor location | Age (yrs) | Weight (kg) | IF |
| 4×1011 | 1 | 1.1 | day 4 | OCS | Oral-maxilla | 9.1 | 25.0 | + |
| 4×1011 | 1 | 1.2 | day 4 | **PCT | Oral-maxilla | 12.0 | 29.6 | − |
| 4×1011 | 1 | 1.3 | day 4 | **BCT | L Forelimb | 14.1 | 32.7 | + |
| 4×1011 | 1 | 1.4 | day 4 | OS | R Proximal Humerus | 7.0 | 30.3 | − |
| 4×1011 | 1 | 1.5 | day 4 | NST (STS) | R Forelimb | 8.1 | 37.2 | − |
| 4×1011 | 1 | 1.6 | day 4 | STS | R Hindlimb | 11.0 | 36.4 | − |
| 8×1011 | 2 | 1.7 | day 4 | NST (STS) | L Forelimb | 12.8 | 32.7 | − |
| 8×1011 | 2 | 1.8 | day 4 | STS | L Hindlimb | 9.9 | 44.0 | − |
| 8×1011 | 2 | 1.9 | day 4 | NST (STS) | R Forelimb | 8.6 | 45.9 | − |
| 1×1012 | 3 | 1.10 | day 4 | FS | Oral-mandibular | 9.4 | 35.0 | N.A. |
| 1×1012 | 3 | 1.11 | day 4 | NST (STS) | R Thorax | 9.6 | 32.0 | − |
| 1×1012 | 3 | 1.12 | day 4 | STS | R Hindlimb | 7.7 | 34.2 | − |
| 5×1012 | 4 | 1.13 | day 4 | OS | L Tibia | 10.1 | 32.6 | + |
| 5×1012 | 4 | 1.14 | day 4 | STS | R Hip/thigh | 12.5 | 16.3 | − |
| 5×1012 | 4 | 1.15 | day 4 | STS | Thorax | 2.7 | 44.9 | + |
| 1×1013 | 5 | 1.16 | day 4 | OS | R Radius | 4.5 | 41.0 | − |
| 1×1013 | 5 | 1.17 | day 4 | STS | R Thorax | 10.7 | 40.0 | + |
| 1×1013 | 5 | 1.18 | day 4 | OS | L humerus | 10.9 | 34.5 | + |
| 4×1011 | 1 | 1.19 | 4–6 hr | OS | R Femur | 10.9 | 33.3 | − |
| 4×1011 | 1 | 1.20 | 4–6 hr | OS | R Tibia | 11.4 | 31.8 | + |
| 4×1011 | 1 | 1.21 | 4–6 hr | OS | R Humerus | 9.5 | 43.0 | − |
| 1×1013 | 5 | 1.22 | 4–6 hr | OS | L Radius | 6.2 | 42.3 | + |
| 1×1013 | 5 | 1.23 | 4–6 hr | OS | R Radius | 9.8 | 61.2 | + |
| 1×1013 | 5 | 1.24 | 4–6 hr | NST | L Axilla | 8.1 | 15.0 | + |
TU: transducing units; IF: immunoflourescent staining for presence of RGD-A-TNF in tumors; OCS: osteochondrosarcoma; PCT: plasma cell tumor; BCT: basal cell tumor; NST: nerve sheath tumor; STS: soft tissue sarcoma; OS: osteosarcoma; FS: fibrosarcoma; N.A.: not analyzed due to improper shipment.
*
Patient I.D.: dog is identified as participating in study 1 (dose escalation study), followed by patient number (i.e. patient 1.2 is dog 2 in study 1 and so on);
**
These two tumors originally diagnosed as soft tissue sarcomas were reclassified upon histopathologic review by a single pathologist (SN).